ClinicalTrials.gg
RecruitingNCT05299879SAINTS-AUpdated Nov 1, 2022

Screening for Advanced Heart Failure IN Stable ouTpatientS - The SAINTS Study

An observational study in Heart Failure With Reduced Ejection Fraction, sponsored by Rigshospitalet, Denmark. Recruiting at 6 sites in Denmark. Open to participants aged 19 Years to 74 Years. Per ClinicalTrials.gov, last updated 2022-11-01.

Sponsored by Rigshospitalet, Denmark · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Oct 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
19 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Heart Failure by Rigshospitalet, Denmark — 4 open to participants now, 4 under way, none of them phase 3. Heart Failure · Rigshospitalet, Denmark.

Started
2022
the only one that year
Observational
6 of 17
2 open now
Registered
15th of 17
by date

Among the 17 studies in Heart Failure by Rigshospitalet, Denmark, this one is the only one that started in 2022, is one of 6 observational ones, and was the 15th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

4 of the 17 studies in Heart Failure by Rigshospitalet, Denmark are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 19 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Heart Failure by Rigshospitalet, Denmark, or all of them as a file.
02

Study summary

The purpose of the Screening for Advanced heart failure IN stable ouTpatientS (SAINTS) study is to determine the prevalence of advanced heart failure (HF) in symptomatic patients with HF and reduced left ventricular ejection fraction (HFrEF), corresponding to the New York Heart Association functional class II-III.

Recognition of advanced HF is a challenge for physicians and under referral for advanced management is a considerable problem. There are excellent treatment options for patients with advanced HF, i.e. heart transplantation or left ventricular assist device (LVAD) implantation, and outcomes with these therapies are considerably better if patients are treated before irreversible end-organ damage occurs. International consensus highlights the importance of timely recognition and referral of these patients to advanced HF centers.

The investigators aim to screen patients with symptomatic HFrEF who are followed in Danish HF clinics in the Copenhagen region with echocardiography, cardiopulmonary exercise test, 6 minute walk test, and NT-proBNP. The investigators hypothesize that 20% of patients with symptomatic heart failure followed in HF clinics in the Copenhagen Region will fulfill the modified criteria for advanced HF from the HFA-ESC (primary end-point in the study)(Reference 1). Patients who are identified with advanced HF will be offered right heart catheterization, guided by ultrasound and inserted through the internal jugular vein, determining pulmonary capillary wedge pressure, cardiac index, central venous pressure, mean pulmonary artery pressure, and central venous oxygen saturation. Patients not fulfilling criteria for advanced HF will be offered right heart catheterization consecutively until 50 patients have been examined (this group will be a comparator group to the patients with advanced HF).

Patients identified with advanced HF will be offered listing for HTx or LVAD if an indication without a contraindication is present. Patients who fulfill the primary endpoint of modified HFA-ESC criteria for advanced HF, and are ineligible for, or unwilling to undergo HTx or LVAD implantation will be invited to participate in the SAINTS B study.

Read the detailed description

Number of patients and sample size More than 3000 patients are followed in the HF clinics on Zealand including the greater Copenhagen region. The investigators plan to include 400 patients in the primary outcome analysis (SAINTS A) and hypothesize that 20% will fulfill the modified criteria for advanced HF.

Statistical analysis Descriptive statistics will be reported as mean +/- standard deviation (SD) or median (interquartile range (IQR)) depending on distribution. Comparisons between groups at baseline will be performed by unpaired t-tests for normally distributed continuous variables, by the Mann-Whitney U test (Wilcoxon rank-sum) for non-normally distributed continuous variables and χ2 or Fisher's exact test for categorical variables.

The primary outcome will be analyzed as the proportion n (%) of included patients who fulfill the modified HFA-ESC criteria for advanced HF. As for secondary outcomes, the investigators will analyze the proportion n (%) of patients who within the first 3 months are; 1) offered heart transplant listing, 2) offered LVAD implantation, 3) listed for HTx and 4) undergoing LVAD implantation. Further, comparisons of invasive hemodynamics, CPET measures, 6MWT, QoL and NTproBNP levels between patients with and without advanced HF will be made using an unpaired t-test or the Mann-Whitney U test for non-normally distributed continuous variables.

03

Conditions studied

  • Heart Failure With Reduced Ejection Fraction

Browse trials for

Keywords

  • Advanced heart failure
  • Screening
04

Who can participate

Ages eligible
19 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients followed in Danish HF clinics in the Copenhagen region.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. History of Chronic heart failure > 3 months
  2. Stable (no hospitalization last 3 months) functional class II-III
  3. HFrEF patients ( (LVEF) ≤ 30%)
  4. On or attempted betablocker and Renin-Angiotensin System (RAS) inhibitor treatment

Exclusion criteria

Exclusion Criteria:

  1. (BMI) > 40 kg/m2
  2. Chronic renal replacement therapy or estimated (eGFR) \< 15 ml/min/1.73m2
  3. Cardiac Resynchronization Therapy (CRT) implantation \< 3 months ago or planned CRT
  4. Severe primary valvular disease
  5. On waiting list for heart transplantation or referred for evaluation
  6. Cancer or other severe non-cardiac disease with estimated less than 1 year
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Symptomatic patients with HFrEF corresponding to NYHA II-III

    Diagnostic Test: Cardiopulmonary exercise test, NT-proBNP, Echocardiography, 6 minute walk test, Right heart catheterization

Interventions

  • Diagnostic testCardiopulmonary exercise test, NT-proBNP, Echocardiography, 6 minute walk test, Right heart catheterization

    Screening for advanced HF with modified criteria from the Heart Failure Association of the European Society of Cardiology

06

What researchers measure

Primary outcomes

  1. Proportion of patients screened who fulfill advanced HF criteria using a modified HFA-ESC definition

    Modified HFA-ESC criteria for advanced HF defined as: • LVEF ≤ 30% as estimated by echocardiography AND • Peak oxygen uptake (VO2peak) \< 12 ml/kg/min (14 if on betablocker) with a Respiratory Exchange Ratio (RER) \> 1.05 OR \< 50% expected for age and gender OR 6 minute walk test (6MWT) distance \< 300 meters AND • N-terminal pro B-type natriuretic peptide (NTproBNP) \> 2000 pg / ml

    Time frame: At time of screening

Secondary outcomes

  1. Proportion of patients offered heart transplant listing < 3 months after primary outcome

    Time frame: 3 months after meeting modified HFA-ESC criteria for advanced HF

  2. Proportion of patients offered LVAD implantation < 3 months after primary outcome

    Time frame: 3 months after meeting modified HFA-ESC criteria for advanced HF

  3. Proportion of patients listed for heart transplantation < 3 months after primary outcome

    Time frame: 3 months after meeting modified HFA-ESC criteria for advanced HF

  4. Proportion of patients undergoing LVAD implantation < 3 months after primary outcome

    Time frame: 3 months after meeting modified HFA-ESC criteria for advanced HF

  5. Pulmonary capillary wedge pressure (PCWP) in mmHg compared between patients with, and without advanced HF

    Measured during right heart catheterization

    Time frame: Within 30 days from screening

  6. Cardiac index (CI) in l/min/m2 compared between patients with, and without advanced HF

    Measured during right heart catheterization

    Time frame: Within 30 days from screening

  7. Central venous pressure (CVP) in mmHg compared between patients with, and without advanced HF

    Measured during right heart catheterization

    Time frame: Within 30 days from screening

  8. Mean pulmonary artery pressure (mPAP) in mmHg compared between patients with, and without advanced HF

    Measured during right heart catheterization

    Time frame: Within 30 days from screening

  9. Central venous oxygen saturation in % compared between patients with, and without advanced HF

    Measured during right heart catheterization

    Time frame: Within 30 days from screening

  10. Peak oxygen uptake (VO2peak) in ml/kg/min compared between patients with, and without advanced HF

    Measured during cardiopulmonary exercise test

    Time frame: At time of screening

  11. Peak respiratory exhange ratio compared between patients with, and without advanced HF

    The ratio between metabolic production of CO2 and the uptake of O2 measured during cardiopulmonary exercise test

    Time frame: At time of screening

  12. Minute ventilation-to-carbon dioxide output slope (VE/VCO2) compared between patients with, and without advanced HF

    The ratio between metabolic production of CO2 and the uptake of O2 measured during cardiopulmonary exercise test

    Time frame: At time of screening

  13. Peak Borg scale score compared between patients with, and without advanced HF

    The Borg scale score is a rating of perceived exertion on a scale from 6-20, with 6 representing at rest, and 20 the most strenuous exercise imaginable. Measured during cardiopulmonary exercise test

    Time frame: At time of screening

  14. 6 minute walk test compared between patients with, and without advanced HF

    Time frame: At screening

  15. Quality of Life (Kansas City Cardiomyopathy Questionnaire (KCCQ)

    Time frame: At screening

  16. NT-proBNP compared between patients with, and without advanced HF

    Time frame: At screening

07

Study locations

1 of 6 sites recruiting
  • Bispebjerg-Frederiksberg Hospital
    Copenhagen, 2400, Denmark
    Not yet recruiting
    • Olav Wendelbo Nielsen, MD, ph.d, dr.med. · Contact
  • Amager/Hvidovre Hospital
    Copenhagen, 2650, Denmark
    Not yet recruiting
    • Morten Petersen, MD, ph.d · Contact
  • Herlev and Gentofte Hospital
    Copenhagen, 2730, Denmark
    Not yet recruiting
    • Morten Schou, MD, ph.d · Contact
  • Glostrup Hospital
    Glostrup, 2600, Denmark
    Recruiting
    • Anders Barasa, MD, ph.d · Contact
  • Nordsjællands Hospital Hillerød
    Hillerød, 3400, Denmark
    Not yet recruiting
    • Nis Stride, MD, ph.d · Contact
  • Zeeland University Hospital Roskilde
    Roskilde, 4000, Denmark
    Not yet recruiting
    • Nadia Dridi · Contact
08

References and documents

Publications

  • Crespo-Leiro MG, Metra M, Lund LH, Milicic D, Costanzo MR, Filippatos G, Gustafsson F, Tsui S, Barge-Caballero E, De Jonge N, Frigerio M, Hamdan R, Hasin T, Hulsmann M, Nalbantgil S, Potena L, Bauersachs J, Gkouziouta A, Ruhparwar A, Ristic AD, Straburzynska-Migaj E, McDonagh T, Seferovic P, Ruschitzka F. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018 Nov;20(11):1505-1535. doi: 10.1002/ejhf.1236. Epub 2018 Jul 17. PubMed 29806100 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Dec 2025, 38 months after the start.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 38 months is below that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2022
First posted
Mar 29, 2022
StartActual
Oct 24, 2022
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Nov 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05299879
Collaborators
Novo Nordisk A/S
Responsible party
Finn Gustafsson (Sponsor-Investigator, Rigshospitalet, Denmark) — Principal investigator
First posted
Mar 29, 2022
Start date
Oct 24, 2022
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Nov 1, 2022

Study contacts

Finn Gustafsson, MD, PhD, DMSci
Contact
finng@dadlnet.dk
+45 35459743
Johan Larsson, MD
Contact
johanlarsson923@gmail.com
+45 50298907
Finn Gustafsson, MD, PhD, DMSci
principal investigator · Rigshospitalet, Denmark

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion